OPDC3 / Oncopeptides - LARVOL DELTA

Efficacy of the Peptide Drug Conjugates Melflufen and OPDC3 in Venetoclax Resistant Acute Myeloid Leukemia (ASH 2024) - "Background : The combination of BCL2 inhibitor venetoclax with a hypomethylating agent (azacitidine or decitabine) or low dose cytarabine has transformed acute myeloid leukemia (AML) treatment, especially for older patients who are unfit for intensive chemotherapy. For OPDC3, the proportion of the HSC/prog like cells, HSC/MPP cells and neutrophils in the samples showed significant association with the drug response. Conclusion : Based on ex vivo, functional assessment, the peptide drug conjugates melflufen and OPDC3 are highly active in AML, especially in models with primary or acquired resistance to venetoclax and support further investigations of these drugs in venetoclax-resistant AML."

Clinical • IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • ANXA5 • CD14 • CD34 • KIT • PTPRC

The Novel Peptide Drug Conjugate OPDC3 Is Highly Active in Different Hematological Malignancies (ASH 2022) - "Melflufen, which was recently approved by the European Medicines Agency for relapsed refractory multiple myeloma patients, is one such PDC that allows for targeted delivery of the payload drug melphalan. OPDC3 can efficiently target patient derived AML and MDS blast cells at relatively low nM concentrations. It is also able to kill more differentiated malignant CD14+ AML cells. Especially in R/R AML samples in which the blast cells and CD14+ cells are resistant to venetoclax, OPDC3 was effective at targeting both cell populations."

Acute Myelogenous Leukemia • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • ANXA5 • CD14

Oncopeptides presents new scientific data at the Annual American Society of Hematology Meeting ASH (PRNewswire) - P3 | N=495 | OCEAN (NCT03151811) | Sponsor: Oncopeptides AB | "Oncopeptides AB...announces that the company presents new scientific data including one clinical abstract and three preclinical research posters at the Annual American Society of Hematology Meeting, ASH, in New Orleans, Louisiana, USA, on December 10-13. The clinical abstract evaluated patients with multiple myeloma who were refractory to prior alkylators in the phase 3 OCEAN study. Data shows that melflufen is a safe and effective therapy in patients who are alkylator refractory, regardless of whether they received a prior autologous stem cell transplant or not. The preclinical posters are based on the Company's proprietary technology platforms for Peptide Drug Conjugate, PDC, and for NK-cell engagers, 'Small Polypeptide based Killer Engagers', SPiKE and have been materialized through partnerships with leading research institutions in Finland, Norway, and Sweden."

P3 data • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology